A Proof-of -Concept Open-Label Clinical Trial of Spleen Tyrosine Kinase Antagonism using Fostamatinib in Moderate-to-Severe Hidradenitis Suppurativa

Published: 6 June 2023| Version 1 | DOI: 10.17632/g5bg3z5993.1
Contributor:
John Frew

Description

Supplementary Files and Data

Files

Categories

Dermatology, Immunity, Hidradenitis Suppurativa

Licence